Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000530325
Ethics application status
Approved
Date submitted
5/04/2017
Date registered
11/04/2017
Date last updated
14/03/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of dynamic clot formation in Endoscopic Mucosal Resection
Scientific title
Evaluation of dynamic clot formation in Endoscopic Mucosal Resection
Secondary ID [1] 291631 0
nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
sessile polyp 302753 0
bleeding 302754 0
hyperfibrinolysis 302755 0
Condition category
Condition code
Oral and Gastrointestinal 302271 302271 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 302272 302272 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Blood 302295 302295 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
In theory electro surgery can increase plasminogen activity and cause hyperfibrinolysis..
viscoelastic testing on 3 occasions, which is not part of standard care, might confirm this hypothesis which has not been previously demonstrated in humans.
Viscoelastic testing is assessing whole blood clotting. At our hospital this is done by Thrombelastomerty with ROTEM by our Pathology provider. Only 4 ml of blood is required and the test can be done for up to 4 hours after the sample is taken.
Intervention code [1] 297718 0
Early detection / Screening
Comparator / control treatment
no control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 301681 0
coagulation abnormality detected by Thrombelastometry
Timepoint [1] 301681 0
post procedural , before discharge from hospital within 2 hours of EMR, and on day two post EMR
Secondary outcome [1] 333549 0
bleeding, noted by patient, prompting contacting the hospital and/or re-admission
Timepoint [1] 333549 0
2-3 days post procedure

Eligibility
Key inclusion criteria
patients undergoing EMR for large sessile colonic polyps
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients on anticoagulants or antiplatelet agents

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
Analysis will be descriptive

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/05/2017
Actual
19/07/2017
Date of last participant enrolment
Anticipated
31/01/2018
Actual
7/02/2018
Date of last data collection
Anticipated
28/02/2018
Actual
10/02/2018
Sample size
Target
30
Accrual to date
Final
33
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 7776 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment postcode(s) [1] 15709 0
5112 - Elizabeth Vale

Funding & Sponsors
Funding source category [1] 296132 0
Hospital
Name [1] 296132 0
Anaesthesia research fund
Country [1] 296132 0
Australia
Funding source category [2] 296940 0
Government body
Name [2] 296940 0
South Australian PBM council
Country [2] 296940 0
Australia
Primary sponsor type
Hospital
Name
Lyell McEwin
Address
Haydown Rd
Elizabeth Vale SA 5112
Country
Australia
Secondary sponsor category [1] 295028 0
None
Name [1] 295028 0
Address [1] 295028 0
Country [1] 295028 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 297377 0
Human Research Ethics Committee (TQEH/LMH/MH)
Ethics committee address [1] 297377 0
Ethics committee country [1] 297377 0
Australia
Date submitted for ethics approval [1] 297377 0
27/03/2017
Approval date [1] 297377 0
07/04/2017
Ethics approval number [1] 297377 0
HREC/17/TQEH/66

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 73850 0
A/Prof Bernd Froessler
Address 73850 0
Lyell McEwin Hospital
Haydown Road
Elizabeth Vale SA 5112
Country 73850 0
Australia
Phone 73850 0
+61881829806
Fax 73850 0
Email 73850 0
[email protected]
Contact person for public queries
Name 73851 0
Bernd Froessler
Address 73851 0
Lyell McEwin Hospital
Haydown Road
Elizabeth Vale SA 5112
Country 73851 0
Australia
Phone 73851 0
+61881829806
Fax 73851 0
Email 73851 0
[email protected]
Contact person for scientific queries
Name 73852 0
Bernd Froessler
Address 73852 0
Lyell McEwin Hospital
Haydown Road
Elizabeth Vale SA 5112
Country 73852 0
Australia
Phone 73852 0
+61881829806
Fax 73852 0
Email 73852 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes 372698-(Uploaded-17-02-2020-16-23-07)-Journal results publication.pdf

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseDynamic functional clot formation in patients undergoing endoscopic mucosal resection.2020https://dx.doi.org/10.1002/jgh3.12306
N.B. These documents automatically identified may not have been verified by the study sponsor.